Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Tryptamine Therapeutics ( (AU:TYP) ).
Tryptamine Therapeutics Limited has announced a change in the director’s interest, specifically for Jason Carroll, through the allotment of capital raising shares and options. The company has increased its ordinary fully paid shares by 15 million and options by 7.5 million, as approved by shareholders, which reflects a strategic move to bolster its capital structure.
More about Tryptamine Therapeutics
YTD Price Performance: -15.79%
Average Trading Volume: 1,658,752
Technical Sentiment Signal: Buy
Current Market Cap: A$40.85M
For an in-depth examination of TYP stock, go to TipRanks’ Stock Analysis page.